{"id":2462,"date":"2019-11-07T15:35:33","date_gmt":"2019-11-07T15:35:33","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/~ACP\/?page_id=2462"},"modified":"2019-11-07T15:35:33","modified_gmt":"2019-11-07T15:35:33","slug":"%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc105","status":"publish","type":"page","link":"https:\/\/plaza.umin.ac.jp\/~ACP\/home\/a-homepage-section\/acp-japan-chapter-public-relations-committee-2019%e5%b9%b4%e5%ba%a6%e6%b4%bb%e5%8b%95%e6%96%b9%e9%87%9d\/in-the-clinic-season2-%e6%a5%ad%e5%8b%99%e3%83%95%e3%83%ad%e3%83%bc\/%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc105","title":{"rendered":"\u8907\u5408\u8a9e\u5019\u88dcITC105"},"content":{"rendered":"\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
\u8907\u5408\u8a9e<\/th>\u30b9\u30b3\u30a2<\/th>\n<\/tr>\n<\/thead>\n
parkinson disease<\/td>4873.9532875902<\/td>\n<\/tr>\n
motor symptoms<\/td>274.92855969454<\/td>\n<\/tr>\n
diagnosis of parkinson disease<\/td>131.1076379839<\/td>\n<\/tr>\n
nonmotor symptoms<\/td>117.09629619592<\/td>\n<\/tr>\n
advanced parkinson disease<\/td>92.360517132268<\/td>\n<\/tr>\n
dopamine agonists<\/td>89.363274830466<\/td>\n<\/tr>\n
motor symptoms of parkinson<\/td>78.553707474711<\/td>\n<\/tr>\n
deep-brain stimulation<\/td>74.59684088845<\/td>\n<\/tr>\n
movement disorder society<\/td>71.500218606488<\/td>\n<\/tr>\n
motor fluctuations<\/td>63.689520441348<\/td>\n<\/tr>\n
management of parkinson disease<\/td>56.006132917313<\/td>\n<\/tr>\n
early parkinson disease<\/td>48.074220598332<\/td>\n<\/tr>\n
symptoms of parkinson disease<\/td>44.183475729254<\/td>\n<\/tr>\n
parkinson disease psychosis<\/td>43.793122353099<\/td>\n<\/tr>\n
motor symptoms of parkinson disease<\/td>40.926595225105<\/td>\n<\/tr>\n
diagnostic criteria<\/td>40.204427506014<\/td>\n<\/tr>\n
international parkinson<\/td>40.165107725478<\/td>\n<\/tr>\n
mov disord<\/td>38.875307273543<\/td>\n<\/tr>\n
advanced disease<\/td>37.177109557799<\/td>\n<\/tr>\n
dopaminergic medications<\/td>36.85007236267<\/td>\n<\/tr>\n
h time<\/td>32.967457529573<\/td>\n<\/tr>\n
controlled trial<\/td>32.76486247049<\/td>\n<\/tr>\n
disease progression<\/td>30.122360469268<\/td>\n<\/tr>\n
red flags<\/td>30.084824744691<\/td>\n<\/tr>\n
nonmotor symptoms of parkinson disease<\/td>29.862232570191<\/td>\n<\/tr>\n
family history of parkinson disease<\/td>29.129990989197<\/td>\n<\/tr>\n
dopamine therapy<\/td>28.460498941515<\/td>\n<\/tr>\n
behavior disorder<\/td>27.906971808138<\/td>\n<\/tr>\n
treatment of parkinson disease<\/td>26.475911363772<\/td>\n<\/tr>\n
quality of life<\/td>25.226892457611<\/td>\n<\/tr>\n
causes of parkinson disease<\/td>25.065305441736<\/td>\n<\/tr>\n
clinical diagnosis of parkinson disease<\/td>24.651882389253<\/td>\n<\/tr>\n
early symptoms of parkinson disease<\/td>23.834767078921<\/td>\n<\/tr>\n
essential tremor<\/td>23.354562846086<\/td>\n<\/tr>\n
symptoms of parkinsonism<\/td>23.280814202913<\/td>\n<\/tr>\n
core motor symptoms<\/td>22.953728061385<\/td>\n<\/tr>\n
mao-b inhibitors<\/td>22.133638394006<\/td>\n<\/tr>\n
american academy of neurology<\/td>21.955834260138<\/td>\n<\/tr>\n
health care<\/td>21.534253083821<\/td>\n<\/tr>\n
mild parkinson disease<\/td>21.414630753325<\/td>\n<\/tr>\n
vascular disease<\/td>21.299725353165<\/td>\n<\/tr>\n
motor complications<\/td>21.229840147116<\/td>\n<\/tr>\n
cause of parkinson disease<\/td>20.871458184133<\/td>\n<\/tr>\n
parkinson disease medicines<\/td>20.246777850204<\/td>\n<\/tr>\n
clinical diagnosis of parkinson<\/td>19.980023098479<\/td>\n<\/tr>\n
urine storage symptoms<\/td>19.946814328438<\/td>\n<\/tr>\n
et al<\/td>19.798989873223<\/td>\n<\/tr>\n
parkinson disease exclusion criteria<\/td>19.422733651409<\/td>\n<\/tr>\n
parkinson risk<\/td>18.934013359849<\/td>\n<\/tr>\n
medical therapy<\/td>18.914832180063<\/td>\n<\/tr>\n
rest tremor<\/td>18.896333544557<\/td>\n<\/tr>\n
movement disorder society task force<\/td>18.334321806849<\/td>\n<\/tr>\n
drug therapy<\/td>18.18463954209<\/td>\n<\/tr>\n
alzheimer disease<\/td>17.910862695365<\/td>\n<\/tr>\n
pathologic progression of parkinson disease<\/td>17.612331327197<\/td>\n<\/tr>\n
pathogenesis of parkinson disease<\/td>17.37931212307<\/td>\n<\/tr>\n
suspected parkinson disease<\/td>17.37931212307<\/td>\n<\/tr>\n
gastrointestinal symptoms<\/td>17.144642578193<\/td>\n<\/tr>\n
quality standards subcommittee<\/td>16.754274167162<\/td>\n<\/tr>\n
nonmotor features of parkinson<\/td>16.720012830768<\/td>\n<\/tr>\n
early parkinson fs disease<\/td>16.607407763625<\/td>\n<\/tr>\n
non-motor symptoms of parkinson<\/td>16.586227650737<\/td>\n<\/tr>\n
management of motor symptoms<\/td>16.474967959271<\/td>\n<\/tr>\n
disease patients<\/td>16.309275921902<\/td>\n<\/tr>\n
advanced parkinson fs disease<\/td>16.11424380966<\/td>\n<\/tr>\n
many features of parkinson disease<\/td>15.786666764889<\/td>\n<\/tr>\n
differential diagnosis of parkinson disease<\/td>15.715064154396<\/td>\n<\/tr>\n
clinical parkinsonism<\/td>15.640401453375<\/td>\n<\/tr>\n
progression of motor symptoms<\/td>15.470883348849<\/td>\n<\/tr>\n
parkinson study group<\/td>15.137044729979<\/td>\n<\/tr>\n
early motor complications<\/td>14.996704033586<\/td>\n<\/tr>\n
formal diagnosis of parkinson disease<\/td>14.938422933029<\/td>\n<\/tr>\n
orthostatic hypotension<\/td>14.400822974714<\/td>\n<\/tr>\n
common neurodegenerative disorder<\/td>14.005686295698<\/td>\n<\/tr>\n
evidence-based medicine review<\/td>13.830348602001<\/td>\n<\/tr>\n
new onset parkinson disease<\/td>13.321779770767<\/td>\n<\/tr>\n
motor system disorder<\/td>13.055352029391<\/td>\n<\/tr>\n
sporadic parkinson fs disease<\/td>13.021607304025<\/td>\n<\/tr>\n
specific symptoms<\/td>12.688455161287<\/td>\n<\/tr>\n
mechanisms of parkinson<\/td>12.661937868693<\/td>\n<\/tr>\n
movement-disorder neurologist<\/td>12.585385134583<\/td>\n<\/tr>\n
adjunct therapy<\/td>12.485374350864<\/td>\n<\/tr>\n
curr opin neurol<\/td>12.446568035622<\/td>\n<\/tr>\n
n engl j med<\/td>12.442410160626<\/td>\n<\/tr>\n
olfactory dysfunction<\/td>12.354362477551<\/td>\n<\/tr>\n
primary outcome<\/td>12.247448713916<\/td>\n<\/tr>\n
seppi k<\/td>12.145481106843<\/td>\n<\/tr>\n
clinical practice<\/td>12.055173868372<\/td>\n<\/tr>\n
other side effects<\/td>11.975180662096<\/td>\n<\/tr>\n
prevalence of parkinson<\/td>11.783260906255<\/td>\n<\/tr>\n
many patients<\/td>11.695646941582<\/td>\n<\/tr>\n
physical therapy<\/td>11.618950038622<\/td>\n<\/tr>\n
disease psychosis<\/td>11.444022210305<\/td>\n<\/tr>\n
supportive criteria<\/td>11.420262287518<\/td>\n<\/tr>\n
lancet neurol<\/td>11.337800126734<\/td>\n<\/tr>\n
autonomic dysfunction<\/td>11.018921819719<\/td>\n<\/tr>\n
braak h<\/td>10.767126541911<\/td>\n<\/tr>\n
care excellence<\/td>10.669676460234<\/td>\n<\/tr>\n
disease subcommittee<\/td>10.649862676582<\/td>\n<\/tr>\n
unified parkinson<\/td>10.647378163949<\/td>\n<\/tr>\n
direct pathologic effects of parkinson disease<\/td>10.63546486221<\/td>\n<\/tr>\n
impulse control disorder<\/td>10.305782432253<\/td>\n<\/tr>\n
emergence of motor symptoms<\/td>10.224723453215<\/td>\n<\/tr>\n
recurrence of motor symptoms<\/td>10.224723453215<\/td>\n<\/tr>\n
ongoing motor symptoms<\/td>10.224723453215<\/td>\n<\/tr>\n
intrusion of motor symptoms<\/td>10.224723453215<\/td>\n<\/tr>\n
delayed greemergent h tremor of parkinson disease<\/td>9.8023335195667<\/td>\n<\/tr>\n
prevalence of parkinson disease increases<\/td>9.7648279134894<\/td>\n<\/tr>\n
evidence-based review of management of motor symptoms<\/td>9.7393028255346<\/td>\n<\/tr>\n
disease course<\/td>9.6232372527296<\/td>\n<\/tr>\n
evidence of efficacy<\/td>9.3905074804397<\/td>\n<\/tr>\n
hauser ra<\/td>9.3613892772829<\/td>\n<\/tr>\n
facial expression<\/td>9.3613892772829<\/td>\n<\/tr>\n
lang ae<\/td>9.3613892772829<\/td>\n<\/tr>\n
progressive motor<\/td>9.2767515810116<\/td>\n<\/tr>\n
common adverse effect<\/td>9.2393419304495<\/td>\n<\/tr>\n
nat rev neurol<\/td>9.1088741075542<\/td>\n<\/tr>\n
dopamine transporter<\/td>8.9720926873273<\/td>\n<\/tr>\n
fox sh<\/td>8.9442719099992<\/td>\n<\/tr>\n
lack of benefit<\/td>8.7388518907318<\/td>\n<\/tr>\n
j neurol<\/td>8.732101131047<\/td>\n<\/tr>\n
volkmann j<\/td>8.6007539225133<\/td>\n<\/tr>\n
clinical history<\/td>8.568349862833<\/td>\n<\/tr>\n
physical examination<\/td>8.4519397417838<\/td>\n<\/tr>\n
atypical parkinsonism<\/td>8.3648922729551<\/td>\n<\/tr>\n
premotor symptoms<\/td>8.3494730511412<\/td>\n<\/tr>\n
common symptoms<\/td>8.3494730511412<\/td>\n<\/tr>\n
adequate control of motor symptoms<\/td>8.3150990581531<\/td>\n<\/tr>\n
cognitive impairment<\/td>8.3026954513854<\/td>\n<\/tr>\n
balance symptoms<\/td>8.1072009288422<\/td>\n<\/tr>\n
hard-to-control disease<\/td>8.0921457089563<\/td>\n<\/tr>\n
wilson disease<\/td>8.0921457089563<\/td>\n<\/tr>\n
tremor-predominant disease<\/td>8.0921457089563<\/td>\n<\/tr>\n
disease duration<\/td>8.0921457089563<\/td>\n<\/tr>\n
motor disability<\/td>8.0655950722289<\/td>\n<\/tr>\n
mg of l-dopa<\/td>8.0310685457409<\/td>\n<\/tr>\n
cognitive deficits<\/td>7.7970979610547<\/td>\n<\/tr>\n
other gpremotor h symptoms<\/td>7.7933519146605<\/td>\n<\/tr>\n
clinical diagnostic criteria<\/td>7.7800168123931<\/td>\n<\/tr>\n
neuropathological assessment of parkinson<\/td>7.6827219664325<\/td>\n<\/tr>\n
freezing of gait<\/td>7.6673172509553<\/td>\n<\/tr>\n
sleep disorders<\/td>7.6539711303027<\/td>\n<\/tr>\n
history of head trauma<\/td>7.6517247310896<\/td>\n<\/tr>\n
katzenschlager r<\/td>7.5446005780976<\/td>\n<\/tr>\n
mood symptoms<\/td>7.5446005780976<\/td>\n<\/tr>\n
such nonmotor symptoms<\/td>7.5389716958717<\/td>\n<\/tr>\n
motor skills<\/td>7.5058819657661<\/td>\n<\/tr>\n
history of exposure<\/td>7.4833147735479<\/td>\n<\/tr>\n
adjunct medications<\/td>7.4448388728168<\/td>\n<\/tr>\n
contralateral side<\/td>7.4448388728168<\/td>\n<\/tr>\n
core motor features<\/td>7.4376249540514<\/td>\n<\/tr>\n
rapid clinical course<\/td>7.4352798091322<\/td>\n<\/tr>\n
jenner p. non-motor features of parkinson disease<\/td>7.388204267999<\/td>\n<\/tr>\n
national institutes of health<\/td>7.2494296105731<\/td>\n<\/tr>\n
urinary symptoms<\/td>7.2084342424043<\/td>\n<\/tr>\n
significant nonmotor symptoms<\/td>7.1860294058534<\/td>\n<\/tr>\n
deep-brain stimulation group<\/td>7.1718695814885<\/td>\n<\/tr>\n
clinical trial<\/td>7.1680492684314<\/td>\n<\/tr>\n
mild cognitive impairment<\/td>7.1450577591353<\/td>\n<\/tr>\n
dopamine agonist<\/td>7.1352426900163<\/td>\n<\/tr>\n
concomitant sleep disorder<\/td>7.0573495735677<\/td>\n<\/tr>\n
arch neurol<\/td>7.0340079263114<\/td>\n<\/tr>\n
jama neurol<\/td>7.0340079263114<\/td>\n<\/tr>\n
parkinson study group precept investigators<\/td>7.0152924554953<\/td>\n<\/tr>\n
initial treatment<\/td>6.9992710231612<\/td>\n<\/tr>\n
motor pathway<\/td>6.7823299831253<\/td>\n<\/tr>\n
treatment of sleep disorders<\/td>6.6412202171354<\/td>\n<\/tr>\n
risk factor<\/td>6.6195018392937<\/td>\n<\/tr>\n
drug management<\/td>6.5934915059146<\/td>\n<\/tr>\n
mood disorder<\/td>6.5777363359721<\/td>\n<\/tr>\n
study group<\/td>6.5777363359721<\/td>\n<\/tr>\n
dose of l-dopa<\/td>6.5315739309452<\/td>\n<\/tr>\n
rapid eye movement sleep behavior disorder<\/td>6.4632345829234<\/td>\n<\/tr>\n
side effect<\/td>6.4474195909412<\/td>\n<\/tr>\n
diagnostic exclusion criteria<\/td>6.4282549860643<\/td>\n<\/tr>\n
neurologic examination<\/td>6.4021717458874<\/td>\n<\/tr>\n
new clinical diagnostic criteria<\/td>6.3552561177301<\/td>\n<\/tr>\n
medication-refractory symptoms<\/td>6.3442275806434<\/td>\n<\/tr>\n
bloem br<\/td>6.3442275806434<\/td>\n<\/tr>\n
dopamine transporter imaging<\/td>6.3376633710643<\/td>\n<\/tr>\n
cognitive decline<\/td>6.3086842910598<\/td>\n<\/tr>\n
stepwise adjustment of parkinson medications<\/td>6.2955545763877<\/td>\n<\/tr>\n
cholinesterase inhibitors<\/td>6.2603383202932<\/td>\n<\/tr>\n
side effects<\/td>6.2603383202932<\/td>\n<\/tr>\n
several motor outcomes<\/td>6.2250291989976<\/td>\n<\/tr>\n
exclusion criteria<\/td>6.1919769884393<\/td>\n<\/tr>\n
advanced deep-brain stimulation therapy<\/td>6.1621435496555<\/td>\n<\/tr>\n
functional impairment<\/td>6.160140576482<\/td>\n<\/tr>\n
exercise benefits motor<\/td>6.0853816070709<\/td>\n<\/tr>\n
cognitive side effects<\/td>6.0834628357098<\/td>\n<\/tr>\n
common gastrointestinal symptoms<\/td>6.0409611796005<\/td>\n<\/tr>\n
chaudhuri kr<\/td>6<\/td>\n<\/tr>\n
bilateral deep-brain stimulation<\/td>5.9718951528454<\/td>\n<\/tr>\n
movement disorder society evidence-based medicine committee<\/td>5.9686673280936<\/td>\n<\/tr>\n
homayoun h<\/td>5.957892135529<\/td>\n<\/tr>\n
related disorders<\/td>5.9436557324017<\/td>\n<\/tr>\n
atypical parkinsonian syndromes<\/td>5.9235304387295<\/td>\n<\/tr>\n
catechol-o-methyl transferase inhibitors<\/td>5.8833655068658<\/td>\n<\/tr>\n
immediate-release drug<\/td>5.803009260803<\/td>\n<\/tr>\n
medication side effects<\/td>5.7689982812296<\/td>\n<\/tr>\n
nontremor symptoms<\/td>5.7326567532262<\/td>\n<\/tr>\n
positive symptoms<\/td>5.7326567532262<\/td>\n<\/tr>\n
important side effect of dopamine agonists<\/td>5.6574926690858<\/td>\n<\/tr>\n
progressive neurologic disorder<\/td>5.6566240480853<\/td>\n<\/tr>\n
nonmotor complications<\/td>5.6513218670805<\/td>\n<\/tr>\n
neurogenic orthostatic hypotension<\/td>5.6420260246804<\/td>\n<\/tr>\n
medical history<\/td>5.5950828130598<\/td>\n<\/tr>\n
presynaptic dopamine<\/td>5.5836291546126<\/td>\n<\/tr>\n
adverse effects<\/td>5.5663153674275<\/td>\n<\/tr>\n
initial use of dopamine agonists<\/td>5.530171462735<\/td>\n<\/tr>\n
other gait disorders<\/td>5.5131462990388<\/td>\n<\/tr>\n
lewy body dementia<\/td>5.4989185479944<\/td>\n<\/tr>\n
ma j<\/td>5.4953924101089<\/td>\n<\/tr>\n
reversible causes<\/td>5.4216120216591<\/td>\n<\/tr>\n
medication-related motor complications<\/td>5.4214586731343<\/td>\n<\/tr>\n
uncontrolled motor complications<\/td>5.4214586731343<\/td>\n<\/tr>\n
recent-onset motor fluctuations<\/td>5.4214586731343<\/td>\n<\/tr>\n
long-term motor complications<\/td>5.4214586731343<\/td>\n<\/tr>\n
h periods<\/td>5.3835632709553<\/td>\n<\/tr>\n
new diagnostic criteria<\/td>5.3778905874053<\/td>\n<\/tr>\n
marek k<\/td>5.3446902355676<\/td>\n<\/tr>\n
kieburtz k<\/td>5.3446902355676<\/td>\n<\/tr>\n
adverse medication effects<\/td>5.33433655068<\/td>\n<\/tr>\n
late manifestation of disease progression<\/td>5.2945268929646<\/td>\n<\/tr>\n
national institute<\/td>5.26429605181<\/td>\n<\/tr>\n
stern m<\/td>5.26429605181<\/td>\n<\/tr>\n
coelho m<\/td>5.26429605181<\/td>\n<\/tr>\n
good motor function<\/td>5.259195040932<\/td>\n<\/tr>\n
restless leg syndrome<\/td>5.2414827884178<\/td>\n<\/tr>\n
addition of dopamine agonists<\/td>5.1854053341415<\/td>\n<\/tr>\n
removal of dopamine agonists<\/td>5.1854053341415<\/td>\n<\/tr>\n
subthalamic nucleus<\/td>5.1800401282227<\/td>\n<\/tr>\n
disease-modifying therapies<\/td>5.1800401282227<\/td>\n<\/tr>\n
medical management<\/td>5.1436867236104<\/td>\n<\/tr>\n
symptomatic management<\/td>5.1436867236104<\/td>\n<\/tr>\n
general neurologist<\/td>5.0914597900437<\/td>\n<\/tr>\n
disease rating scale<\/td>5.0783090600187<\/td>\n<\/tr>\n
dopamine breakdown<\/td>5.0453784915223<\/td>\n<\/tr>\n
bilateral stimulation<\/td>5.0453784915223<\/td>\n<\/tr>\n
dopamine deficiency<\/td>5.0453784915223<\/td>\n<\/tr>\n
precept study<\/td>4.9979987988788<\/td>\n<\/tr>\n
prion disorder<\/td>4.9979987988788<\/td>\n<\/tr>\n
tolerability of deep-brain stimulation therapy<\/td>4.9795084648368<\/td>\n<\/tr>\n
postural tremor<\/td>4.9737947036147<\/td>\n<\/tr>\n
dopaminergic goff h periods<\/td>4.9541639996482<\/td>\n<\/tr>\n
practice parameter<\/td>4.8989794855664<\/td>\n<\/tr>\n
isaacson s<\/td>4.8989794855664<\/td>\n<\/tr>\n
idiopathic rem sleep behavior disorder<\/td>4.8955667380178<\/td>\n<\/tr>\n
absence of nonmotor features<\/td>4.8856589973663<\/td>\n<\/tr>\n
neurologist care<\/td>4.8645985581956<\/td>\n<\/tr>\n
clinical outcomes<\/td>4.8427346405845<\/td>\n<\/tr>\n
atypical neurodegenerative parkinsonism<\/td>4.839811562999<\/td>\n<\/tr>\n
alternative diagnosis<\/td>4.8205705136679<\/td>\n<\/tr>\n
formulations of l-dopa<\/td>4.7753019278348<\/td>\n<\/tr>\n
secondary nonmotor neurodegenerative causes<\/td>4.7451515679786<\/td>\n<\/tr>\n
gwearing-off h effect<\/td>4.7398963239353<\/td>\n<\/tr>\n
neurodegenerative syndrome<\/td>4.7381372205376<\/td>\n<\/tr>\n
atypical neurodegenerative parkinsonian disorders<\/td>4.7184639854049<\/td>\n<\/tr>\n
oral immediate-release l-dopa<\/td>4.7101756871628<\/td>\n<\/tr>\n
weintraub d<\/td>4.6806946386414<\/td>\n<\/tr>\n
other medications<\/td>4.6806946386414<\/td>\n<\/tr>\n
patient information<\/td>4.6806946386414<\/td>\n<\/tr>\n
bilateral subthalamic stimulation<\/td>4.6196709652247<\/td>\n<\/tr>\n
clinical presentation<\/td>4.5799756509618<\/td>\n<\/tr>\n
dopaminergic therapies<\/td>4.5590141139096<\/td>\n<\/tr>\n
zach h<\/td>4.5270190558379<\/td>\n<\/tr>\n
reichmann h<\/td>4.5270190558379<\/td>\n<\/tr>\n
h state<\/td>4.5270190558379<\/td>\n<\/tr>\n
h period<\/td>4.5270190558379<\/td>\n<\/tr>\n
h gsluggishness<\/td>4.5270190558379<\/td>\n<\/tr>\n
bruschini h<\/td>4.5270190558379<\/td>\n<\/tr>\n
williams h<\/td>4.5270190558379<\/td>\n<\/tr>\n
moderate disease severity<\/td>4.5242590318911<\/td>\n<\/tr>\n
poor sleep<\/td>4.4609134425734<\/td>\n<\/tr>\n
long-acting dopaminergic drug<\/td>4.4510182535424<\/td>\n<\/tr>\n
medication-induced dyskinesia<\/td>4.4267276788013<\/td>\n<\/tr>\n
evidence-based review<\/td>4.4267276788013<\/td>\n<\/tr>\n
quality-of-life scores<\/td>4.4267276788013<\/td>\n<\/tr>\n
surgical interventions<\/td>4.4267276788013<\/td>\n<\/tr>\n
weiner wj<\/td>4.4267276788013<\/td>\n<\/tr>\n
pulsatile stimulation of dopamine receptors<\/td>4.397983489376<\/td>\n<\/tr>\n
breathing sleep disorders<\/td>4.3594283666312<\/td>\n<\/tr>\n
nighttime sleep disorders<\/td>4.3594283666312<\/td>\n<\/tr>\n
atypical features<\/td>4.3558771746929<\/td>\n<\/tr>\n
learned motor skills<\/td>4.3030146004678<\/td>\n<\/tr>\n
perlmutter j<\/td>4.3003769612566<\/td>\n<\/tr>\n
123i-ioflupane dopamine transporter spect<\/td>4.2988861033349<\/td>\n<\/tr>\n
nonmotor disability<\/td>4.294076025711<\/td>\n<\/tr>\n
movement-disorder specialist<\/td>4.2813902858562<\/td>\n<\/tr>\n
clinical setting<\/td>4.2621475953544<\/td>\n<\/tr>\n
number of patients<\/td>4.2621475953544<\/td>\n<\/tr>\n
absence of exclusion criteria<\/td>4.2484406376281<\/td>\n<\/tr>\n
longitudinal study<\/td>4.2027992734195<\/td>\n<\/tr>\n
double-blind study<\/td>4.2027992734195<\/td>\n<\/tr>\n
placebo-controlled study<\/td>4.2027992734195<\/td>\n<\/tr>\n
open-label study<\/td>4.2027992734195<\/td>\n<\/tr>\n
rapid eye movement<\/td>4.1854601371357<\/td>\n<\/tr>\n
globus pallidus interna<\/td>4.1601676461038<\/td>\n<\/tr>\n
injectable dopamine agonist<\/td>4.1601676461038<\/td>\n<\/tr>\n
quality-of-life score<\/td>4.1195342878142<\/td>\n<\/tr>\n
troublesome dyskinesia<\/td>4.1195342878142<\/td>\n<\/tr>\n
presence of bradykinesia<\/td>4.1195342878142<\/td>\n<\/tr>\n
alternative diagnoses<\/td>4.1195342878142<\/td>\n<\/tr>\n
differential diagnosis<\/td>4.0536004644211<\/td>\n<\/tr>\n
exclusion criteria rules<\/td>4.049546885517<\/td>\n<\/tr>\n
123i-ioflupane dopamine transporter spect imaging<\/td>4.0428232170799<\/td>\n<\/tr>\n
l-dopa doses<\/td>4.0155342728704<\/td>\n<\/tr>\n
management of bladder dysfunction<\/td>3.999837223024<\/td>\n<\/tr>\n
several years of l-dopa use<\/td>3.9908790767727<\/td>\n<\/tr>\n
okun ms. deep-brain stimulation<\/td>3.9600573257325<\/td>\n<\/tr>\n
cpn study group<\/td>3.9405421141402<\/td>\n<\/tr>\n
earlystim study group<\/td>3.9405421141402<\/td>\n<\/tr>\n
pd study group<\/td>3.9405421141402<\/td>\n<\/tr>\n
special attention<\/td>3.9359793425309<\/td>\n<\/tr>\n
brundin p<\/td>3.9359793425309<\/td>\n<\/tr>\n
urinary incontinence<\/td>3.9359793425309<\/td>\n<\/tr>\n
dopaminergic drugs<\/td>3.9359793425309<\/td>\n<\/tr>\n
poewe w<\/td>3.9359793425309<\/td>\n<\/tr>\n
timmermann l<\/td>3.9359793425309<\/td>\n<\/tr>\n
typical parkinsonian gait<\/td>3.9148676411689<\/td>\n<\/tr>\n
panicker j<\/td>3.8858292384691<\/td>\n<\/tr>\n
schill j<\/td>3.8858292384691<\/td>\n<\/tr>\n
fukasaka j<\/td>3.8858292384691<\/td>\n<\/tr>\n
ferreira j<\/td>3.8858292384691<\/td>\n<\/tr>\n
aharon-peretz j<\/td>3.8858292384691<\/td>\n<\/tr>\n
send?n j<\/td>3.8858292384691<\/td>\n<\/tr>\n
jankovic j<\/td>3.8858292384691<\/td>\n<\/tr>\n
rau j<\/td>3.8858292384691<\/td>\n<\/tr>\n
seibyl j<\/td>3.8858292384691<\/td>\n<\/tr>\n
cummings j<\/td>3.8858292384691<\/td>\n<\/tr>\n
health care professional<\/td>3.8701091424451<\/td>\n<\/tr>\n
clinical findings<\/td>3.8512851068431<\/td>\n<\/tr>\n
clinical guidelines<\/td>3.8512851068431<\/td>\n<\/tr>\n
clinical efficiency<\/td>3.8512851068431<\/td>\n<\/tr>\n
clinical relevance<\/td>3.8512851068431<\/td>\n<\/tr>\n
drug administration<\/td>3.8336586254776<\/td>\n<\/tr>\n
j neurol neurosurg psychiatry<\/td>3.8321775894993<\/td>\n<\/tr>\n
early use<\/td>3.8067540958393<\/td>\n<\/tr>\n
survival study<\/td>3.7976578442319<\/td>\n<\/tr>\n
neurol clin<\/td>3.7792667089114<\/td>\n<\/tr>\n
presence of parkinsonism<\/td>3.7792667089114<\/td>\n<\/tr>\n
vascular parkinsonism<\/td>3.7792667089114<\/td>\n<\/tr>\n
movement disorders emergencies<\/td>3.7788985119798<\/td>\n<\/tr>\n
multidisciplinary care<\/td>3.7606030930864<\/td>\n<\/tr>\n
balance therapy<\/td>3.7606030930864<\/td>\n<\/tr>\n
agonist therapy<\/td>3.7606030930864<\/td>\n<\/tr>\n
patients experience<\/td>3.7511661226171<\/td>\n<\/tr>\n
nonergot dopamine agonists ropinirole<\/td>3.7472768667293<\/td>\n<\/tr>\n
long-acting l-dopa<\/td>3.7368757062242<\/td>\n<\/tr>\n
l-dopa regimen<\/td>3.7368757062242<\/td>\n<\/tr>\n
several other pathologic conditions<\/td>3.723629783182<\/td>\n<\/tr>\n
wearing-off effects<\/td>3.7224194364084<\/td>\n<\/tr>\n
daytime hypersomnolence<\/td>3.7224194364084<\/td>\n<\/tr>\n
diagnostic tool<\/td>3.7224194364084<\/td>\n<\/tr>\n
ahlskog je<\/td>3.7224194364084<\/td>\n<\/tr>\n
united states<\/td>3.7224194364084<\/td>\n<\/tr>\n
good quality of life<\/td>3.7062880231628<\/td>\n<\/tr>\n
irregular release of dopamine<\/td>3.7062880231628<\/td>\n<\/tr>\n
hours of goff h time<\/td>3.6852485896495<\/td>\n<\/tr>\n
alternate diagnosis<\/td>3.6628415014847<\/td>\n<\/tr>\n
correct diagnosis<\/td>3.6628415014847<\/td>\n<\/tr>\n
patient fs<\/td>3.6628415014847<\/td>\n<\/tr>\n
accuracy of diagnosis<\/td>3.6628415014847<\/td>\n<\/tr>\n
patients experience fluctuations<\/td>3.6529276674218<\/td>\n<\/tr>\n
several medications<\/td>3.6423205736757<\/td>\n<\/tr>\n
immediate-release formulations<\/td>3.6002057436785<\/td>\n<\/tr>\n
early fluctuations<\/td>3.6002057436785<\/td>\n<\/tr>\n
presynaptic dopaminergic system<\/td>3.5953592505049<\/td>\n<\/tr>\n
new symptomatic therapies<\/td>3.5953592505049<\/td>\n<\/tr>\n
adverse effect profile<\/td>3.5953592505049<\/td>\n<\/tr>\n
cognitive function<\/td>3.5840246342157<\/td>\n<\/tr>\n
formulations?oral extended-release l-dopa<\/td>3.5345904677365<\/td>\n<\/tr>\n
vascular disorders<\/td>3.5341188430494<\/td>\n<\/tr>\n
irreversible adverse effects<\/td>3.5254687665352<\/td>\n<\/tr>\n
serious adverse effects<\/td>3.5254687665352<\/td>\n<\/tr>\n
recent evidence-based review<\/td>3.5254687665352<\/td>\n<\/tr>\n
other information<\/td>3.4996355115806<\/td>\n<\/tr>\n
other medicines<\/td>3.4996355115806<\/td>\n<\/tr>\n
parkinsonism relat disord<\/td>3.4773390964968<\/td>\n<\/tr>\n
typical clinical presentation<\/td>3.4747117108611<\/td>\n<\/tr>\n
intrajejunal infusion of l-dopa gel<\/td>3.4708216345141<\/td>\n<\/tr>\n
base of gait<\/td>3.4641016151377<\/td>\n<\/tr>\n
postuma rb<\/td>3.4641016151377<\/td>\n<\/tr>\n
arm swings<\/td>3.4641016151377<\/td>\n<\/tr>\n
halliday gm<\/td>3.4641016151377<\/td>\n<\/tr>\n
minneap minn<\/td>3.4641016151377<\/td>\n<\/tr>\n
kalia lv<\/td>3.4641016151377<\/td>\n<\/tr>\n
first step<\/td>3.4641016151377<\/td>\n<\/tr>\n
peripheral tissues<\/td>3.4641016151377<\/td>\n<\/tr>\n
lim sy<\/td>3.4641016151377<\/td>\n<\/tr>\n
holloway rg<\/td>3.4641016151377<\/td>\n<\/tr>\n
gparkinsonism hyperpyrexia syndrome h<\/td>3.4519247197843<\/td>\n<\/tr>\n
management advances<\/td>3.4397906282504<\/td>\n<\/tr>\n
secondary parkinsonism<\/td>3.4149529703483<\/td>\n<\/tr>\n
dream phase of sleep<\/td>3.4142280776924<\/td>\n<\/tr>\n
good sleep hygiene<\/td>3.4142280776924<\/td>\n<\/tr>\n
controlled-release l-dopa<\/td>3.3766483753852<\/td>\n<\/tr>\n
sustained-release l-dopa<\/td>3.3766483753852<\/td>\n<\/tr>\n
conversion of l-dopa<\/td>3.3766483753852<\/td>\n<\/tr>\n
dopamine-blocking medications<\/td>3.3635856610149<\/td>\n<\/tr>\n
multicenter controlled trial<\/td>3.3604214537127<\/td>\n<\/tr>\n
early premotor<\/td>3.3503689588345<\/td>\n<\/tr>\n
supportive therapy<\/td>3.3437015248821<\/td>\n<\/tr>\n
disease-modifying treatment<\/td>3.3437015248821<\/td>\n<\/tr>\n
early autonomic deficits<\/td>3.3334377695972<\/td>\n<\/tr>\n
van hilten j<\/td>3.3318160522188<\/td>\n<\/tr>\n
other conditions<\/td>3.3097509196469<\/td>\n<\/tr>\n
international continence society<\/td>3.3036235909394<\/td>\n<\/tr>\n
decreased quality of life<\/td>3.3019272488946<\/td>\n<\/tr>\n
prolongation of medication effect<\/td>3.3019272488946<\/td>\n<\/tr>\n
alternative cause of parkinsonism<\/td>3.2706211157025<\/td>\n<\/tr>\n
pathologic changes<\/td>3.2531531233956<\/td>\n<\/tr>\n
neuroprotective effect<\/td>3.2237097954706<\/td>\n<\/tr>\n
future neurol<\/td>3.1779718278113<\/td>\n<\/tr>\n
prominent tremor<\/td>3.1779718278113<\/td>\n<\/tr>\n
front neurol<\/td>3.1779718278113<\/td>\n<\/tr>\n
medication-refractory tremor<\/td>3.1779718278113<\/td>\n<\/tr>\n
gastrointestinal tract<\/td>3.1622776601684<\/td>\n<\/tr>\n
few patients<\/td>3.1543421455299<\/td>\n<\/tr>\n
detailed history<\/td>3.1463462836458<\/td>\n<\/tr>\n
thorough history<\/td>3.1463462836458<\/td>\n<\/tr>\n
controlled trial of rasagiline<\/td>3.14083560495<\/td>\n<\/tr>\n
somatic features of depression<\/td>3.14083560495<\/td>\n<\/tr>\n
emergent essential tremor<\/td>3.1364581089052<\/td>\n<\/tr>\n
dopaminergic projections<\/td>3.1301691601466<\/td>\n<\/tr>\n
stepwise progression<\/td>3.1301691601466<\/td>\n<\/tr>\n
dopaminergic blockers<\/td>3.1301691601466<\/td>\n<\/tr>\n
enteral gel therapy<\/td>3.1072325059539<\/td>\n<\/tr>\n
clinical slide set<\/td>3.0956162091134<\/td>\n<\/tr>\n
complete lack of progression<\/td>3.0861636884341<\/td>\n<\/tr>\n
andante study investigators<\/td>3.0668124740328<\/td>\n<\/tr>\n
bilateral deep brain stimulation vs<\/td>3.0514051588559<\/td>\n<\/tr>\n
proper sleep hygiene<\/td>3.0417314178549<\/td>\n<\/tr>\n
other dopamine-blocking antipsychotic agents<\/td>3.0350549753166<\/td>\n<\/tr>\n
pathologic involvement<\/td>3.0274001040351<\/td>\n<\/tr>\n
refined criteria<\/td>3.0274001040351<\/td>\n<\/tr>\n
mild depression<\/td>3.0274001040351<\/td>\n<\/tr>\n
sufficient dose<\/td>3.0274001040351<\/td>\n<\/tr>\n
mandatory criteria<\/td>3.0274001040351<\/td>\n<\/tr>\n
early manifestation<\/td>3.0274001040351<\/td>\n<\/tr>\n
exclusionary criteria<\/td>3.0274001040351<\/td>\n<\/tr>\n
mao-b inhibitors selegiline<\/td>3.0261714988458<\/td>\n<\/tr>\n
further gait deficits<\/td>3.0182390421613<\/td>\n<\/tr>\n
increased risk<\/td>2.9906975624424<\/td>\n<\/tr>\n
symptom control<\/td>2.9906975624424<\/td>\n<\/tr>\n
new mixed mao-b inhibitor<\/td>2.975475652329<\/td>\n<\/tr>\n
onset of movements<\/td>2.9718278662008<\/td>\n<\/tr>\n
passive joint movement<\/td>2.9595672453546<\/td>\n<\/tr>\n
treatment of anxiety<\/td>2.9428309563827<\/td>\n<\/tr>\n
rapid-onset gait impairment<\/td>2.9416827534329<\/td>\n<\/tr>\n
expert opin drug saf<\/td>2.9278526754426<\/td>\n<\/tr>\n
sudden worsening of parkinsonism<\/td>2.913792159502<\/td>\n<\/tr>\n
acute worsening of parkinsonism<\/td>2.913792159502<\/td>\n<\/tr>\n
wearing-off time<\/td>2.9129506302439<\/td>\n<\/tr>\n
double-blind trial<\/td>2.9129506302439<\/td>\n<\/tr>\n
memory impairment<\/td>2.9129506302439<\/td>\n<\/tr>\n
alterations of gait<\/td>2.9129506302439<\/td>\n<\/tr>\n
secondary causes<\/td>2.9129506302439<\/td>\n<\/tr>\n
medication regimen<\/td>2.9129506302439<\/td>\n<\/tr>\n
effective medication<\/td>2.9129506302439<\/td>\n<\/tr>\n
intestinal gel<\/td>2.9129506302439<\/td>\n<\/tr>\n
lang a<\/td>2.9129506302439<\/td>\n<\/tr>\n
red flags rules<\/td>2.9041912218409<\/td>\n<\/tr>\n
autonomic function<\/td>2.8925076085191<\/td>\n<\/tr>\n
physiol rev<\/td>2.8925076085191<\/td>\n<\/tr>\n
intestinal gel formulations<\/td>2.8844991406148<\/td>\n<\/tr>\n
equivalent dose of immediate-release carbidopa?l<\/td>2.8777854609598<\/td>\n<\/tr>\n
lower-body parkinsonism<\/td>2.8716217110259<\/td>\n<\/tr>\n
drug-induced parkinsonism<\/td>2.8716217110259<\/td>\n<\/tr>\n
refractory tremor<\/td>2.8716217110259<\/td>\n<\/tr>\n
symmetrical parkinsonism<\/td>2.8716217110259<\/td>\n<\/tr>\n
current symptomatic therapies<\/td>2.8536385282275<\/td>\n<\/tr>\n
effective symptomatic therapies<\/td>2.8536385282275<\/td>\n<\/tr>\n
treated patients<\/td>2.8502698827718<\/td>\n<\/tr>\n
elderly patients<\/td>2.8502698827718<\/td>\n<\/tr>\n
individual patients<\/td>2.8502698827718<\/td>\n<\/tr>\n
obstructive sleep apnea<\/td>2.8429702849739<\/td>\n<\/tr>\n
stepwise assessment<\/td>2.8284271247462<\/td>\n<\/tr>\n
further dose adjustment<\/td>2.8210130123402<\/td>\n<\/tr>\n
immediate-release carbidopa-levodopa<\/td>2.8173132472613<\/td>\n<\/tr>\n
immediate-release formulation<\/td>2.8173132472613<\/td>\n<\/tr>\n
normal functional imaging<\/td>2.8172691138478<\/td>\n<\/tr>\n
oral extended-release carbidopa?l<\/td>2.7981664143395<\/td>\n<\/tr>\n
severe fluctuations<\/td>2.7831576837137<\/td>\n<\/tr>\n
other genes<\/td>2.7831576837137<\/td>\n<\/tr>\n
other considerations<\/td>2.7831576837137<\/td>\n<\/tr>\n
vitamin d<\/td>2.7831576837137<\/td>\n<\/tr>\n
other non?l<\/td>2.7831576837137<\/td>\n<\/tr>\n
other doctors<\/td>2.7831576837137<\/td>\n<\/tr>\n
common form of psychosis<\/td>2.7494592739972<\/td>\n<\/tr>\n
clin drug investig<\/td>2.7494592739972<\/td>\n<\/tr>\n
scheduled dose<\/td>2.7355647997348<\/td>\n<\/tr>\n
early stages<\/td>2.7355647997348<\/td>\n<\/tr>\n
last dose<\/td>2.7355647997348<\/td>\n<\/tr>\n
low dose<\/td>2.7355647997348<\/td>\n<\/tr>\n
reflexive eye movements<\/td>2.7322193018926<\/td>\n<\/tr>\n
several medicines<\/td>2.7232698153315<\/td>\n<\/tr>\n
standard surgical therapy<\/td>2.7144176165949<\/td>\n<\/tr>\n
initial therapies<\/td>2.7108060108295<\/td>\n<\/tr>\n
dopa gel<\/td>2.7108060108295<\/td>\n<\/tr>\n
postural imbalance<\/td>2.7108060108295<\/td>\n<\/tr>\n
postural reflexes<\/td>2.7108060108295<\/td>\n<\/tr>\n
large subset of patients<\/td>2.7098746210941<\/td>\n<\/tr>\n
early bulbar deficits<\/td>2.7052932225631<\/td>\n<\/tr>\n
dopaminergic therapy?for example<\/td>2.6960123091946<\/td>\n<\/tr>\n
recessive disorders<\/td>2.6853496142827<\/td>\n<\/tr>\n
hypokinetic disorders<\/td>2.6853496142827<\/td>\n<\/tr>\n
repetitive movements<\/td>2.6853496142827<\/td>\n<\/tr>\n
patient fs reaction<\/td>2.66716827534<\/td>\n<\/tr>\n
rescue therapy<\/td>2.6591479484725<\/td>\n<\/tr>\n
known treatment<\/td>2.6591479484725<\/td>\n<\/tr>\n
treatment of constipation<\/td>2.6591479484725<\/td>\n<\/tr>\n
functional outcomes<\/td>2.6591479484725<\/td>\n<\/tr>\n
urinary tract<\/td>2.6591479484725<\/td>\n<\/tr>\n
nat rev neurosci<\/td>2.6546748825543<\/td>\n<\/tr>\n
medication responsiveness<\/td>2.632148025905<\/td>\n<\/tr>\n
antinausea medications<\/td>2.632148025905<\/td>\n<\/tr>\n
medication-induced complications<\/td>2.632148025905<\/td>\n<\/tr>\n
goal-directed behavior<\/td>2.632148025905<\/td>\n<\/tr>\n
orthostatic lightheadedness<\/td>2.632148025905<\/td>\n<\/tr>\n
rate of progression<\/td>2.632148025905<\/td>\n<\/tr>\n
dopa medications<\/td>2.632148025905<\/td>\n<\/tr>\n
common premotor symptom<\/td>2.6207413942089<\/td>\n<\/tr>\n
alternative causes of imbalance<\/td>2.6207413942089<\/td>\n<\/tr>\n
peak drug level<\/td>2.6207413942089<\/td>\n<\/tr>\n
medical errors?may lead<\/td>2.6153209720237<\/td>\n<\/tr>\n
complete neurologic examination<\/td>2.6084654714896<\/td>\n<\/tr>\n
nat rev dis primers<\/td>2.6018209830256<\/td>\n<\/tr>\n
physical function<\/td>2.5900200641113<\/td>\n<\/tr>\n
extended-release formulation<\/td>2.5900200641113<\/td>\n<\/tr>\n
atypical signs<\/td>2.5900200641113<\/td>\n<\/tr>\n
extended-release carbidopa-levodopa<\/td>2.5900200641113<\/td>\n<\/tr>\n
advanced stages<\/td>2.5755095769014<\/td>\n<\/tr>\n
many years<\/td>2.5457298950218<\/td>\n<\/tr>\n
health professionals<\/td>2.5457298950218<\/td>\n<\/tr>\n
normal postural reflexes<\/td>2.5423029068338<\/td>\n<\/tr>\n
increase risk<\/td>2.5148668593659<\/td>\n<\/tr>\n
imaging test<\/td>2.5148668593659<\/td>\n<\/tr>\n
medical education<\/td>2.5148668593659<\/td>\n<\/tr>\n
number of steps<\/td>2.5148668593659<\/td>\n<\/tr>\n
passive movements<\/td>2.4989993994394<\/td>\n<\/tr>\n
cerebellar dysfunction<\/td>2.4989993994394<\/td>\n<\/tr>\n
severe untreated depression<\/td>2.4928828716784<\/td>\n<\/tr>\n
environmental risk factors<\/td>2.4928828716784<\/td>\n<\/tr>\n
age-associated pathologic conditions<\/td>2.4643818583473<\/td>\n<\/tr>\n
cubo e. new<\/td>2.4494897427832<\/td>\n<\/tr>\n
presence of dementia<\/td>2.4494897427832<\/td>\n<\/tr>\n
placebo group<\/td>2.4494897427832<\/td>\n<\/tr>\n
presence of freezing<\/td>2.4494897427832<\/td>\n<\/tr>\n
neuropsychiatric complications<\/td>2.4494897427832<\/td>\n<\/tr>\n
concomitant depression<\/td>2.4494897427832<\/td>\n<\/tr>\n
daily wearing-off time<\/td>2.4494897427832<\/td>\n<\/tr>\n
schrag a<\/td>2.4494897427832<\/td>\n<\/tr>\n
antipsychotic benefit<\/td>2.4494897427832<\/td>\n<\/tr>\n
hur k<\/td>2.4147364027664<\/td>\n<\/tr>\n
chi-burris k<\/td>2.4147364027664<\/td>\n<\/tr>\n
sethi k<\/td>2.4147364027664<\/td>\n<\/tr>\n
knudsen k<\/td>2.4147364027664<\/td>\n<\/tr>\n
kochi k<\/td>2.4147364027664<\/td>\n<\/tr>\n
hasegawa k<\/td>2.4147364027664<\/td>\n<\/tr>\n
follett k<\/td>2.4147364027664<\/td>\n<\/tr>\n
selective serotonin reuptake inhibitors<\/td>2.4136903820681<\/td>\n<\/tr>\n
cochrane database syst rev<\/td>2.4052058575179<\/td>\n<\/tr>\n
koller m<\/td>2.3784142300054<\/td>\n<\/tr>\n
respiratory muscle<\/td>2.3784142300054<\/td>\n<\/tr>\n
muscle tone<\/td>2.3784142300054<\/td>\n<\/tr>\n
role of exercise<\/td>2.3784142300054<\/td>\n<\/tr>\n
hellmich m<\/td>2.3784142300054<\/td>\n<\/tr>\n
hallett m<\/td>2.3784142300054<\/td>\n<\/tr>\n
murata m<\/td>2.3784142300054<\/td>\n<\/tr>\n
stamelou m<\/td>2.3784142300054<\/td>\n<\/tr>\n
systematic review<\/td>2.3784142300054<\/td>\n<\/tr>\n
grundman m<\/td>2.3784142300054<\/td>\n<\/tr>\n
politis m<\/td>2.3784142300054<\/td>\n<\/tr>\n
detrusor muscle<\/td>2.3784142300054<\/td>\n<\/tr>\n
munneke m<\/td>2.3784142300054<\/td>\n<\/tr>\n
schootman m<\/td>2.3784142300054<\/td>\n<\/tr>\n
assessment of safety<\/td>2.3784142300054<\/td>\n<\/tr>\n
muscle weakness<\/td>2.3784142300054<\/td>\n<\/tr>\n
balance changes<\/td>2.3784142300054<\/td>\n<\/tr>\n
memory changes<\/td>2.3784142300054<\/td>\n<\/tr>\n
stacy m<\/td>2.3784142300054<\/td>\n<\/tr>\n
auffret m<\/td>2.3784142300054<\/td>\n<\/tr>\n
severe postural instability<\/td>2.376176797565<\/td>\n<\/tr>\n
several cellular mechanisms<\/td>2.3672935308725<\/td>\n<\/tr>\n
braak e. staging of brain pathology<\/td>2.3521580450494<\/td>\n<\/tr>\n
quality-of-life outcomes<\/td>2.3403473193207<\/td>\n<\/tr>\n
pyramidal tract<\/td>2.3403473193207<\/td>\n<\/tr>\n
multidisciplinary team<\/td>2.3403473193207<\/td>\n<\/tr>\n
use of apomorphine<\/td>2.3403473193207<\/td>\n<\/tr>\n
nervous system<\/td>2.3403473193207<\/td>\n<\/tr>\n
protein intake<\/td>2.3403473193207<\/td>\n<\/tr>\n
wheelchair use<\/td>2.3403473193207<\/td>\n<\/tr>\n
fluid intake<\/td>2.3403473193207<\/td>\n<\/tr>\n
normal muscle paralysis<\/td>2.3299861015014<\/td>\n<\/tr>\n
generalized slowing of movements<\/td>2.3201751253057<\/td>\n<\/tr>\n
autonomic functions<\/td>2.3003266337912<\/td>\n<\/tr>\n
available therapies<\/td>2.2795070569548<\/td>\n<\/tr>\n
one exclusion criterion<\/td>2.2787044788325<\/td>\n<\/tr>\n
del tredici k<\/td>2.2677220247015<\/td>\n<\/tr>\n
involuntary movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
erectile dysfunction<\/td>2.2581008643532<\/td>\n<\/tr>\n
limb movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
amplitude of movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
extraocular movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
mitochondrial dysfunction<\/td>2.2581008643532<\/td>\n<\/tr>\n
vestibular dysfunction<\/td>2.2581008643532<\/td>\n<\/tr>\n
direction of movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
rhythm of movements<\/td>2.2581008643532<\/td>\n<\/tr>\n
prior head trauma<\/td>2.2449240966188<\/td>\n<\/tr>\n
disease-modifying drugs<\/td>2.2360679774998<\/td>\n<\/tr>\n
multiple system atrophy<\/td>2.2209061548523<\/td>\n<\/tr>\n
enough vitamin d<\/td>2.2209061548523<\/td>\n<\/tr>\n
depression scales<\/td>2.2133638394006<\/td>\n<\/tr>\n
regular exercise<\/td>2.2133638394006<\/td>\n<\/tr>\n
practice improvement<\/td>2.2133638394006<\/td>\n<\/tr>\n
fahn s<\/td>2.2133638394006<\/td>\n<\/tr>\n
hsu a<\/td>2.2133638394006<\/td>\n<\/tr>\n
finkbeiner s<\/td>2.2133638394006<\/td>\n<\/tr>\n
proven efficacy<\/td>2.2133638394006<\/td>\n<\/tr>\n
shown efficacy<\/td>2.2133638394006<\/td>\n<\/tr>\n
jette n<\/td>2.2133638394006<\/td>\n<\/tr>\n
frolkis a<\/td>2.2133638394006<\/td>\n<\/tr>\n
perez-lloret s<\/td>2.2133638394006<\/td>\n<\/tr>\n
reich s<\/td>2.2133638394006<\/td>\n<\/tr>\n
fasano a<\/td>2.2133638394006<\/td>\n<\/tr>\n
dopamine-refractory depression<\/td>2.2133638394006<\/td>\n<\/tr>\n
eberly s<\/td>2.2133638394006<\/td>\n<\/tr>\n
drapier s<\/td>2.2133638394006<\/td>\n<\/tr>\n
gnonmotor fluctuations<\/td>2.2133638394006<\/td>\n<\/tr>\n
quinn n<\/td>2.2133638394006<\/td>\n<\/tr>\n
corbett a<\/td>2.2133638394006<\/td>\n<\/tr>\n
cecere a<\/td>2.2133638394006<\/td>\n<\/tr>\n
aldakheel a<\/td>2.2133638394006<\/td>\n<\/tr>\n
levodopa adjunct<\/td>2.2133638394006<\/td>\n<\/tr>\n
choudhry a<\/td>2.2133638394006<\/td>\n<\/tr>\n
brice a<\/td>2.2133638394006<\/td>\n<\/tr>\n
overeem s<\/td>2.2133638394006<\/td>\n<\/tr>\n
kell s<\/td>2.2133638394006<\/td>\n<\/tr>\n
efficacy of safinamide<\/td>2.2133638394006<\/td>\n<\/tr>\n
lack of cost-effectiveness<\/td>2.2133638394006<\/td>\n<\/tr>\n
ziemann a<\/td>2.2133638394006<\/td>\n<\/tr>\n
device-related complications<\/td>2.2133638394006<\/td>\n<\/tr>\n
lesage s<\/td>2.2133638394006<\/td>\n<\/tr>\n
administration of botulinum toxin<\/td>2.1822472719434<\/td>\n<\/tr>\n
uniform slowness of movements<\/td>2.1685638970161<\/td>\n<\/tr>\n
several seconds<\/td>2.165736770668<\/td>\n<\/tr>\n
several situations<\/td>2.165736770668<\/td>\n<\/tr>\n
several options<\/td>2.165736770668<\/td>\n<\/tr>\n
several weeks<\/td>2.165736770668<\/td>\n<\/tr>\n
gronseth g<\/td>2.1406951429281<\/td>\n<\/tr>\n
mild unsteadiness<\/td>2.1406951429281<\/td>\n<\/tr>\n
many clinicians<\/td>2.1406951429281<\/td>\n<\/tr>\n
neuroleptic malignant syndrome<\/td>2.1398263878673<\/td>\n<\/tr>\n
u.k. national institute<\/td>2.1398263878673<\/td>\n<\/tr>\n
cortical sensory loss<\/td>2.1398263878673<\/td>\n<\/tr>\n
schrag a. psychosis<\/td>2.1398263878673<\/td>\n<\/tr>\n
multidisciplinary team of clinicians<\/td>2.1169328630255<\/td>\n<\/tr>\n
impaired attention<\/td>2.1147425268811<\/td>\n<\/tr>\n
mills r<\/td>2.1147425268811<\/td>\n<\/tr>\n
cortical signs<\/td>2.1147425268811<\/td>\n<\/tr>\n
recent advances<\/td>2.1147425268811<\/td>\n<\/tr>\n
number of persons<\/td>2.1147425268811<\/td>\n<\/tr>\n
shimazu r<\/td>2.1147425268811<\/td>\n<\/tr>\n
oakes d<\/td>2.1147425268811<\/td>\n<\/tr>\n
silver d<\/td>2.1147425268811<\/td>\n<\/tr>\n
constantinescu r<\/td>2.1147425268811<\/td>\n<\/tr>\n
aarsland d<\/td>2.1147425268811<\/td>\n<\/tr>\n
berg d<\/td>2.1147425268811<\/td>\n<\/tr>\n
savica r<\/td>2.1147425268811<\/td>\n<\/tr>\n
sakakibara r<\/td>2.1147425268811<\/td>\n<\/tr>\n
recent studies<\/td>2.1147425268811<\/td>\n<\/tr>\n
dano r<\/td>2.1147425268811<\/td>\n<\/tr>\n
van der marck ma<\/td>2.1039790110173<\/td>\n<\/tr>\n
24-hour urine copper level<\/td>2.0870738306761<\/td>\n<\/tr>\n
recent technologic advances<\/td>2.0757816311124<\/td>\n<\/tr>\n
additional pertinent information<\/td>2.0757816311124<\/td>\n<\/tr>\n
magnetic resonance imaging<\/td>2.0757816311124<\/td>\n<\/tr>\n
limited oral intake<\/td>2.0757816311124<\/td>\n<\/tr>\n
g?nier marchand d<\/td>2.0757816311124<\/td>\n<\/tr>\n
physical therapist<\/td>2.0597671439071<\/td>\n<\/tr>\n
neurobiol dis<\/td>2.0597671439071<\/td>\n<\/tr>\n
bilateral lesions<\/td>2.0597671439071<\/td>\n<\/tr>\n
placebo-controlled phase<\/td>2.0597671439071<\/td>\n<\/tr>\n
substantia nigra<\/td>2.0597671439071<\/td>\n<\/tr>\n
overactive bladder<\/td>2.0597671439071<\/td>\n<\/tr>\n
ba f<\/td>2.0597671439071<\/td>\n<\/tr>\n
poor mood<\/td>2.0597671439071<\/td>\n<\/tr>\n
bladder infection<\/td>2.0597671439071<\/td>\n<\/tr>\n
volume of speech<\/td>2.0597671439071<\/td>\n<\/tr>\n
university of pittsburgh medical center<\/td>2.0565711885958<\/td>\n<\/tr>\n
intraintestinal infusion of carbidopa?l<\/td>2.0396489026555<\/td>\n<\/tr>\n
global life expectancy<\/td>2.0396489026555<\/td>\n<\/tr>\n
barton b<\/td>2<\/td>\n<\/tr>\n
glutamate-release inhibitor<\/td>2<\/td>\n<\/tr>\n
dopamine-blocking properties<\/td>2<\/td>\n<\/tr>\n
b isoform of monoamine oxidase<\/td>2<\/td>\n<\/tr>\n
typical doses<\/td>2<\/td>\n<\/tr>\n
parkinson-related psychosis<\/td>2<\/td>\n<\/tr>\n
ravina b<\/td>2<\/td>\n<\/tr>\n
longer-acting formulations<\/td>2<\/td>\n<\/tr>\n
nalls ma<\/td>2<\/td>\n<\/tr>\n
mena ma<\/td>2<\/td>\n<\/tr>\n
neuroprotective role<\/td>2<\/td>\n<\/tr>\n
cholinesterase inhibitor pyridostigmine<\/td>2<\/td>\n<\/tr>\n
\u00c3\u00a03-adrenergic agonist<\/td>2<\/td>\n<\/tr>\n
vigorous exercise<\/td>2<\/td>\n<\/tr>\n
first-in-human assessment of prx002<\/td>2<\/td>\n<\/tr>\n
multiple doses<\/td>2<\/td>\n<\/tr>\n
unprovoked psychosis<\/td>2<\/td>\n<\/tr>\n
off balance<\/td>2<\/td>\n<\/tr>\n
anecdotal evidence<\/td>2<\/td>\n<\/tr>\n
creese b<\/td>2<\/td>\n<\/tr>\n
agid y. subthalamic neurostimulation<\/td>1.9839302766304<\/td>\n<\/tr>\n
evening fluid intake<\/td>1.9786024464679<\/td>\n<\/tr>\n
pyramidal tract sign<\/td>1.9786024464679<\/td>\n<\/tr>\n
anticholinergic agents<\/td>1.9679896712654<\/td>\n<\/tr>\n
available drugs<\/td>1.9679896712654<\/td>\n<\/tr>\n
certain medicines<\/td>1.9679896712654<\/td>\n<\/tr>\n
cerebellar signs<\/td>1.9679896712654<\/td>\n<\/tr>\n
antinausea agents<\/td>1.9679896712654<\/td>\n<\/tr>\n
cystoscopic injection of botulinum toxin<\/td>1.9579730911015<\/td>\n<\/tr>\n
progressive supranuclear palsy<\/td>1.9559811771959<\/td>\n<\/tr>\n
anticholinergic agent glycopyrrolate<\/td>1.9441612972397<\/td>\n<\/tr>\n
antiepileptic agent zonisamide<\/td>1.9441612972397<\/td>\n<\/tr>\n
olfactory deficit<\/td>1.9343364202677<\/td>\n<\/tr>\n
loddo g<\/td>1.9343364202677<\/td>\n<\/tr>\n
autoactivation deficits<\/td>1.9343364202677<\/td>\n<\/tr>\n
olfactory bulb<\/td>1.9343364202677<\/td>\n<\/tr>\n
annesi g<\/td>1.9343364202677<\/td>\n<\/tr>\n
progressive decrements<\/td>1.9343364202677<\/td>\n<\/tr>\n
mild nausea<\/td>1.9343364202677<\/td>\n<\/tr>\n
giannini g<\/td>1.9343364202677<\/td>\n<\/tr>\n
progressive aphasia<\/td>1.9343364202677<\/td>\n<\/tr>\n
progressive speeding<\/td>1.9343364202677<\/td>\n<\/tr>\n
calandra-buonaura g<\/td>1.9343364202677<\/td>\n<\/tr>\n
deuschl g<\/td>1.9343364202677<\/td>\n<\/tr>\n
akinetic rigid form<\/td>1.9063685859939<\/td>\n<\/tr>\n
patient handouts<\/td>1.8612097182042<\/td>\n<\/tr>\n
kenney c<\/td>1.8612097182042<\/td>\n<\/tr>\n
vascular parkinsonism?characteristics<\/td>1.8612097182042<\/td>\n<\/tr>\n
unintelligible speech<\/td>1.8612097182042<\/td>\n<\/tr>\n
factor sa<\/td>1.8612097182042<\/td>\n<\/tr>\n
modest benefit<\/td>1.8612097182042<\/td>\n<\/tr>\n
weight loss<\/td>1.8612097182042<\/td>\n<\/tr>\n
mg of carbidopa<\/td>1.8612097182042<\/td>\n<\/tr>\n
additional carbidopa<\/td>1.8612097182042<\/td>\n<\/tr>\n
variable expression<\/td>1.8612097182042<\/td>\n<\/tr>\n
evanoff ba<\/td>1.8612097182042<\/td>\n<\/tr>\n
few studies<\/td>1.8612097182042<\/td>\n<\/tr>\n
healthy diet<\/td>1.8612097182042<\/td>\n<\/tr>\n
rapid withdrawal<\/td>1.8612097182042<\/td>\n<\/tr>\n
psychomotor slowing<\/td>1.8612097182042<\/td>\n<\/tr>\n
speech pathologist<\/td>1.8612097182042<\/td>\n<\/tr>\n
eggers c<\/td>1.8612097182042<\/td>\n<\/tr>\n
troubling dyskinesia<\/td>1.8612097182042<\/td>\n<\/tr>\n
houman homayoun<\/td>1.8612097182042<\/td>\n<\/tr>\n
environmental factors<\/td>1.8612097182042<\/td>\n<\/tr>\n
harris c<\/td>1.8612097182042<\/td>\n<\/tr>\n
lots of water<\/td>1.8612097182042<\/td>\n<\/tr>\n
copper deposits<\/td>1.8612097182042<\/td>\n<\/tr>\n
v?rin m. pharmacological insights<\/td>1.8612097182042<\/td>\n<\/tr>\n
vos ra<\/td>1.8612097182042<\/td>\n<\/tr>\n
loss of motivation<\/td>1.8612097182042<\/td>\n<\/tr>\n
clarke c<\/td>1.8612097182042<\/td>\n<\/tr>\n
significant disability<\/td>1.8612097182042<\/td>\n<\/tr>\n
various factors<\/td>1.8612097182042<\/td>\n<\/tr>\n
ratchet-like resistance<\/td>1.8612097182042<\/td>\n<\/tr>\n
duyckaerts c<\/td>1.8612097182042<\/td>\n<\/tr>\n
zesiewicz t<\/td>1.8612097182042<\/td>\n<\/tr>\n
dr. homayoun<\/td>1.8612097182042<\/td>\n<\/tr>\n
frontotemporal dementia<\/td>1.8612097182042<\/td>\n<\/tr>\n
late-onset dementia<\/td>1.8612097182042<\/td>\n<\/tr>\n
initial monotherapy<\/td>1.8612097182042<\/td>\n<\/tr>\n
single-photon emission<\/td>1.8612097182042<\/td>\n<\/tr>\n
benefits of hypnotics<\/td>1.8612097182042<\/td>\n<\/tr>\n
dietary modification<\/td>1.8612097182042<\/td>\n<\/tr>\n
racette ba<\/td>1.8612097182042<\/td>\n<\/tr>\n
projected number of people<\/td>1.8493111942973<\/td>\n<\/tr>\n
substantia nigra pars<\/td>1.8171205928321<\/td>\n<\/tr>\n
guttman m. effectiveness<\/td>1.8171205928321<\/td>\n<\/tr>\n
positron emission tomography<\/td>1.8171205928321<\/td>\n<\/tr>\n
major dietary restriction<\/td>1.8171205928321<\/td>\n<\/tr>\n
eating lots of fiber<\/td>1.8171205928321<\/td>\n<\/tr>\n
repetitive motion fatigue<\/td>1.7817974362807<\/td>\n<\/tr>\n
lead pipe rigidity<\/td>1.7817974362807<\/td>\n<\/tr>\n
such fine-motor tasks<\/td>1.7817974362807<\/td>\n<\/tr>\n
marks wj jr<\/td>1.7817974362807<\/td>\n<\/tr>\n
called lewy bodies<\/td>1.7817974362807<\/td>\n<\/tr>\n
such structural abnormalities<\/td>1.7817974362807<\/td>\n<\/tr>\n
ipx066 advance-pd investigators<\/td>1.7817974362807<\/td>\n<\/tr>\n
short-term memory problems<\/td>1.7817974362807<\/td>\n<\/tr>\n
variety of signs<\/td>1.7782794100389<\/td>\n<\/tr>\n
close attention<\/td>1.7782794100389<\/td>\n<\/tr>\n
zago w<\/td>1.7782794100389<\/td>\n<\/tr>\n
grossardt br<\/td>1.7782794100389<\/td>\n<\/tr>\n
multidisciplinary approach<\/td>1.7782794100389<\/td>\n<\/tr>\n
krack p<\/td>1.7782794100389<\/td>\n<\/tr>\n
bulk-forming agents<\/td>1.7782794100389<\/td>\n<\/tr>\n
oertel w<\/td>1.7782794100389<\/td>\n<\/tr>\n
normal perception<\/td>1.7782794100389<\/td>\n<\/tr>\n
sambati l<\/td>1.7782794100389<\/td>\n<\/tr>\n
appropriate drugs<\/td>1.7782794100389<\/td>\n<\/tr>\n
severe dystonia<\/td>1.7782794100389<\/td>\n<\/tr>\n
cortelli p<\/td>1.7782794100389<\/td>\n<\/tr>\n
klingelhoefer l<\/td>1.7782794100389<\/td>\n<\/tr>\n
longitudinal follow-up of swedd subjects<\/td>1.7692284081335<\/td>\n<\/tr>\n
multicenter analysis of glucocerebrosidase mutations<\/td>1.7692284081335<\/td>\n<\/tr>\n
slow prion-like pattern of spread<\/td>1.7692284081335<\/td>\n<\/tr>\n
author thanks kelvin l. chou<\/td>1.7411011265923<\/td>\n<\/tr>\n
caregiver stress<\/td>1.7320508075689<\/td>\n<\/tr>\n
prominent unsteadiness<\/td>1.7320508075689<\/td>\n<\/tr>\n
large meals<\/td>1.7320508075689<\/td>\n<\/tr>\n
open-label results<\/td>1.7320508075689<\/td>\n<\/tr>\n
caregiver burden<\/td>1.7320508075689<\/td>\n<\/tr>\n
sufficient fiber<\/td>1.7320508075689<\/td>\n<\/tr>\n
nursing home placement<\/td>1.6983813295649<\/td>\n<\/tr>\n
regular bedtime routine<\/td>1.6983813295649<\/td>\n<\/tr>\n
neurourology promotion committee<\/td>1.6983813295649<\/td>\n<\/tr>\n
high-intensity resistance training<\/td>1.6983813295649<\/td>\n<\/tr>\n
faulty protein degradation<\/td>1.6983813295649<\/td>\n<\/tr>\n
unilateral presentation<\/td>1.6817928305074<\/td>\n<\/tr>\n
reliable test<\/td>1.6817928305074<\/td>\n<\/tr>\n
impaired performance<\/td>1.6817928305074<\/td>\n<\/tr>\n
impaired language<\/td>1.6817928305074<\/td>\n<\/tr>\n
multiple domains<\/td>1.6817928305074<\/td>\n<\/tr>\n
sidransky e<\/td>1.6817928305074<\/td>\n<\/tr>\n
prolonged periods<\/td>1.6817928305074<\/td>\n<\/tr>\n
neuroprotective trials<\/td>1.6817928305074<\/td>\n<\/tr>\n
pull test<\/td>1.6817928305074<\/td>\n<\/tr>\n
daytime naps<\/td>1.6817928305074<\/td>\n<\/tr>\n
corrective steps<\/td>1.6817928305074<\/td>\n<\/tr>\n
ebersbach g. nonpharmacological treatments<\/td>1.6817928305074<\/td>\n<\/tr>\n
united kingdom<\/td>1.6817928305074<\/td>\n<\/tr>\n
increased susceptibility<\/td>1.6817928305074<\/td>\n<\/tr>\n
stooped posture<\/td>1.6817928305074<\/td>\n<\/tr>\n
diet modifications<\/td>1.6817928305074<\/td>\n<\/tr>\n
absence of contraindications<\/td>1.6817928305074<\/td>\n<\/tr>\n
later stages<\/td>1.6817928305074<\/td>\n<\/tr>\n
posture holding<\/td>1.6817928305074<\/td>\n<\/tr>\n
cortical regions<\/td>1.6817928305074<\/td>\n<\/tr>\n
repetitive maneuvers<\/td>1.6817928305074<\/td>\n<\/tr>\n
intestinal absorption<\/td>1.6817928305074<\/td>\n<\/tr>\n
finazzi-agro e<\/td>1.6817928305074<\/td>\n<\/tr>\n
excessive gambling<\/td>1.6817928305074<\/td>\n<\/tr>\n
increased mortality<\/td>1.6817928305074<\/td>\n<\/tr>\n
pesticide exposure<\/td>1.6817928305074<\/td>\n<\/tr>\n
pathology of synucleinopathies<\/td>1.6817928305074<\/td>\n<\/tr>\n
gasser t<\/td>1.6817928305074<\/td>\n<\/tr>\n
additional testing<\/td>1.6817928305074<\/td>\n<\/tr>\n
improved scores<\/td>1.6817928305074<\/td>\n<\/tr>\n
urodynamic studies<\/td>1.6817928305074<\/td>\n<\/tr>\n
excessive sleepiness<\/td>1.6817928305074<\/td>\n<\/tr>\n
duda je<\/td>1.6817928305074<\/td>\n<\/tr>\n
narrow base<\/td>1.6817928305074<\/td>\n<\/tr>\n
excessive sedation<\/td>1.6817928305074<\/td>\n<\/tr>\n
tool kit<\/td>1.6817928305074<\/td>\n<\/tr>\n
pringsheim t<\/td>1.6817928305074<\/td>\n<\/tr>\n
eyal e<\/td>1.6817928305074<\/td>\n<\/tr>\n
professional organizations<\/td>1.6817928305074<\/td>\n<\/tr>\n
shortened steps<\/td>1.6817928305074<\/td>\n<\/tr>\n
anti-a-synuclein monoclonal antibody<\/td>1.5874010519682<\/td>\n<\/tr>\n
unique challenges of dyskinesias<\/td>1.5874010519682<\/td>\n<\/tr>\n
n-methyl-d-aspartate antagonist amantadine<\/td>1.5874010519682<\/td>\n<\/tr>\n
corticobasal ganglionic degeneration<\/td>1.5874010519682<\/td>\n<\/tr>\n
neutral amino acids<\/td>1.5874010519682<\/td>\n<\/tr>\n
irresistible gsleep attacks<\/td>1.5874010519682<\/td>\n<\/tr>\n
reduced stride length<\/td>1.5874010519682<\/td>\n<\/tr>\n
sleep?wake cycle disruption<\/td>1.5874010519682<\/td>\n<\/tr>\n
jansen steur en<\/td>1.5874010519682<\/td>\n<\/tr>\n
norepinephrine prodrug droxidopa<\/td>1.5874010519682<\/td>\n<\/tr>\n
low-hanging fruit of neurodegeneration<\/td>1.5874010519682<\/td>\n<\/tr>\n
agricultural occupations<\/td>1.5650845800733<\/td>\n<\/tr>\n
midbrain involvement<\/td>1.5650845800733<\/td>\n<\/tr>\n
corti o<\/td>1.5650845800733<\/td>\n<\/tr>\n
agricultural industry<\/td>1.5650845800733<\/td>\n<\/tr>\n
economic burden<\/td>1.5650845800733<\/td>\n<\/tr>\n
transdermal patch<\/td>1.5650845800733<\/td>\n<\/tr>\n
fung vs<\/td>1.5650845800733<\/td>\n<\/tr>\n
perlmutter js<\/td>1.5650845800733<\/td>\n<\/tr>\n
healthy volunteers<\/td>1.5650845800733<\/td>\n<\/tr>\n
neuropsychiatric issues<\/td>1.5650845800733<\/td>\n<\/tr>\n
dorsey er<\/td>1.5650845800733<\/td>\n<\/tr>\n
schapira ahv<\/td>1.5650845800733<\/td>\n<\/tr>\n
high-protein meals<\/td>1.5650845800733<\/td>\n<\/tr>\n
supine position<\/td>1.5650845800733<\/td>\n<\/tr>\n
y?benes jg<\/td>1.5650845800733<\/td>\n<\/tr>\n
gronseth gs<\/td>1.5650845800733<\/td>\n<\/tr>\n
nursing homes<\/td>1.5650845800733<\/td>\n<\/tr>\n
selective \u00c2\u00bf<\/td>1.5650845800733<\/td>\n<\/tr>\n
kordower jh<\/td>1.5650845800733<\/td>\n<\/tr>\n
hormonal disturbances<\/td>1.5650845800733<\/td>\n<\/tr>\n
klostermann f<\/td>1.5650845800733<\/td>\n<\/tr>\n
bower jh<\/td>1.5650845800733<\/td>\n<\/tr>\n
mild-to-severe anxiety<\/td>1.5650845800733<\/td>\n<\/tr>\n
rotigotine patch<\/td>1.5650845800733<\/td>\n<\/tr>\n
zesiewicz ta<\/td>1.5650845800733<\/td>\n<\/tr>\n
negative results<\/td>1.5650845800733<\/td>\n<\/tr>\n
oxidative stress<\/td>1.5650845800733<\/td>\n<\/tr>\n
certain things<\/td>1.5650845800733<\/td>\n<\/tr>\n
mass lesions<\/td>1.5650845800733<\/td>\n<\/tr>\n
metabolic disturbances<\/td>1.5650845800733<\/td>\n<\/tr>\n
suchowersky o<\/td>1.5650845800733<\/td>\n<\/tr>\n
current efforts<\/td>1.5650845800733<\/td>\n<\/tr>\n
daily activities<\/td>1.5650845800733<\/td>\n<\/tr>\n
outpatient setting<\/td>1.5650845800733<\/td>\n<\/tr>\n
various strategies<\/td>1.5650845800733<\/td>\n<\/tr>\n
supine hypertension<\/td>1.5650845800733<\/td>\n<\/tr>\n
barbosa er<\/td>1.5650845800733<\/td>\n<\/tr>\n
volume of voice<\/td>1.5650845800733<\/td>\n<\/tr>\n
schapira ah<\/td>1.5650845800733<\/td>\n<\/tr>\n
major source<\/td>1.5650845800733<\/td>\n<\/tr>\n
computed tomography<\/td>1.5650845800733<\/td>\n<\/tr>\n
neurobiol aging<\/td>1.5650845800733<\/td>\n<\/tr>\n
slow pace<\/td>1.5650845800733<\/td>\n<\/tr>\n
japan zonisamide<\/td>1.5650845800733<\/td>\n<\/tr>\n
goldman jg<\/td>1.5650845800733<\/td>\n<\/tr>\n
schuepbach wm<\/td>1.4142135623731<\/td>\n<\/tr>\n
subdural hematoma<\/td>1.4142135623731<\/td>\n<\/tr>\n
disease-specific biomarkers<\/td>1.4142135623731<\/td>\n<\/tr>\n
therapeutic response<\/td>1.4142135623731<\/td>\n<\/tr>\n
parkin mutation<\/td>1.4142135623731<\/td>\n<\/tr>\n
dickson dw<\/td>1.4142135623731<\/td>\n<\/tr>\n
vries nm<\/td>1.4142135623731<\/td>\n<\/tr>\n
borm gf<\/td>1.4142135623731<\/td>\n<\/tr>\n
monogenic causation<\/td>1.4142135623731<\/td>\n<\/tr>\n
mental calculations<\/td>1.4142135623731<\/td>\n<\/tr>\n
fernandez hh<\/td>1.4142135623731<\/td>\n<\/tr>\n
nice guideline<\/td>1.4142135623731<\/td>\n<\/tr>\n
whole grains<\/td>1.4142135623731<\/td>\n<\/tr>\n
gallagher da<\/td>1.4142135623731<\/td>\n<\/tr>\n
ben-shlomo y<\/td>1.4142135623731<\/td>\n<\/tr>\n
upper extremities<\/td>1.4142135623731<\/td>\n<\/tr>\n
neurosurgical approaches<\/td>1.4142135623731<\/td>\n<\/tr>\n
second opinion<\/td>1.4142135623731<\/td>\n<\/tr>\n
ophthalmologic referral<\/td>1.4142135623731<\/td>\n<\/tr>\n
robottom bj<\/td>1.4142135623731<\/td>\n<\/tr>\n
basal ganglia<\/td>1.4142135623731<\/td>\n<\/tr>\n
u.s. food<\/td>1.4142135623731<\/td>\n<\/tr>\n
espay aj<\/td>1.4142135623731<\/td>\n<\/tr>\n
4.6 hours<\/td>1.4142135623731<\/td>\n<\/tr>\n
steeves td<\/td>1.4142135623731<\/td>\n<\/tr>\n
visual misperceptions<\/td>1.4142135623731<\/td>\n<\/tr>\n
aasly jo<\/td>1.4142135623731<\/td>\n<\/tr>\n
polyethylene glycol<\/td>1.4142135623731<\/td>\n<\/tr>\n
modified barium<\/td>1.4142135623731<\/td>\n<\/tr>\n
full spectrum<\/td>1.4142135623731<\/td>\n<\/tr>\n
formed hallucinations<\/td>1.4142135623731<\/td>\n<\/tr>\n
populous nations<\/td>1.4142135623731<\/td>\n<\/tr>\n
stowe rl<\/td>1.4142135623731<\/td>\n<\/tr>\n
iacovelli v<\/td>1.4142135623731<\/td>\n<\/tr>\n
rocca wa<\/td>1.4142135623731<\/td>\n<\/tr>\n
willis aw<\/td>1.4142135623731<\/td>\n<\/tr>\n
sullivan kl<\/td>1.4142135623731<\/td>\n<\/tr>\n
griffith sg<\/td>1.4142135623731<\/td>\n<\/tr>\n
bhatia kp<\/td>1.4142135623731<\/td>\n<\/tr>\n
nocturnal polyuria<\/td>1.4142135623731<\/td>\n<\/tr>\n
exception of quetiapine<\/td>1.4142135623731<\/td>\n<\/tr>\n
high-compression stockings<\/td>1.4142135623731<\/td>\n<\/tr>\n
heavy metals<\/td>1.4142135623731<\/td>\n<\/tr>\n
odds ratio<\/td>1.4142135623731<\/td>\n<\/tr>\n
r?b u<\/td>1.4142135623731<\/td>\n<\/tr>\n
morgan jc<\/td>1.4142135623731<\/td>\n<\/tr>\n
serum ceruloplasmin<\/td>1.4142135623731<\/td>\n<\/tr>\n
neurourol urodyn<\/td>1.4142135623731<\/td>\n<\/tr>\n
light touch<\/td>1.4142135623731<\/td>\n<\/tr>\n
4.8 hours<\/td>1.4142135623731<\/td>\n<\/tr>\n
sexual activity<\/td>1.4142135623731<\/td>\n<\/tr>\n
eszopiclone trazodone<\/td>1.4142135623731<\/td>\n<\/tr>\n
standaert dg<\/td>1.4142135623731<\/td>\n<\/tr>\n
gagnon jf<\/td>1.4142135623731<\/td>\n<\/tr>\n
miyasaki jm<\/td>1.4142135623731<\/td>\n<\/tr>\n
small vessel<\/td>1.4142135623731<\/td>\n<\/tr>\n
off-label indication<\/td>1.4142135623731<\/td>\n<\/tr>\n
hawker rj<\/td>1.4142135623731<\/td>\n<\/tr>\n
dirkx mf<\/td>1.4142135623731<\/td>\n<\/tr>\n
misfolded proteins<\/td>1.4142135623731<\/td>\n<\/tr>\n
schenk db<\/td>1.4142135623731<\/td>\n<\/tr>\n
plasma levels<\/td>1.4142135623731<\/td>\n<\/tr>\n
fink gr<\/td>1.4142135623731<\/td>\n<\/tr>\n
portable pump?have<\/td>1.4142135623731<\/td>\n<\/tr>\n
valproic acid<\/td>1.4142135623731<\/td>\n<\/tr>\n
ives nj<\/td>1.4142135623731<\/td>\n<\/tr>\n
previous version<\/td>1.4142135623731<\/td>\n<\/tr>\n
immediate reinstitution<\/td>1.4142135623731<\/td>\n<\/tr>\n
production of neurotransmitters<\/td>1.4142135623731<\/td>\n<\/tr>\n
focus of development<\/td>1.4142135623731<\/td>\n<\/tr>\n
goetz cg<\/td>1.4142135623731<\/td>\n<\/tr>\n
index finger<\/td>1.4142135623731<\/td>\n<\/tr>\n
helmich rc<\/td>1.4142135623731<\/td>\n<\/tr>\n
brandt md<\/td>1.4142135623731<\/td>\n<\/tr>\n
mason ar<\/td>1.4142135623731<\/td>\n<\/tr>\n
bie rma<\/td>1.4142135623731<\/td>\n<\/tr>\n
1-agonist midodrine<\/td>1.4142135623731<\/td>\n<\/tr>\n
martin wr<\/td>1.4142135623731<\/td>\n<\/tr>\n
potential candidates<\/td>1.4142135623731<\/td>\n<\/tr>\n
salivary glands<\/td>1.4142135623731<\/td>\n<\/tr>\n
jost wh<\/td>1.4142135623731<\/td>\n<\/tr>\n
tanner cm<\/td>1.4142135623731<\/td>\n<\/tr>\n
lozano am<\/td>1.4142135623731<\/td>\n<\/tr>\n
social goals<\/td>1.4142135623731<\/td>\n<\/tr>\n
enactment of dreams<\/td>1.4142135623731<\/td>\n<\/tr>\n
axial mobility<\/td>1.4142135623731<\/td>\n<\/tr>\n
systemic infections<\/td>1.4142135623731<\/td>\n<\/tr>\n
normal-pressure hydrocephalus<\/td>1.4142135623731<\/td>\n<\/tr>\n
korczyn ad<\/td>1.4142135623731<\/td>\n<\/tr>\n
olanow cw<\/td>1.4142135623731<\/td>\n<\/tr>\n
multistep turns<\/td>1.4142135623731<\/td>\n<\/tr>\n
biglan km<\/td>1.4142135623731<\/td>\n<\/tr>\n
incomplete penetrance<\/td>1.4142135623731<\/td>\n<\/tr>\n
evaluation of candidacy<\/td>1.4142135623731<\/td>\n<\/tr>\n
ffytche dh<\/td>1.4142135623731<\/td>\n<\/tr>\n
inspiratory stridor<\/td>1.4142135623731<\/td>\n<\/tr>\n
experimental models<\/td>1.4142135623731<\/td>\n<\/tr>\n
vegetable picker<\/td>1.4142135623731<\/td>\n<\/tr>\n
challenging cases<\/td>1.4142135623731<\/td>\n<\/tr>\n
ness dk<\/td>1.4142135623731<\/td>\n<\/tr>\n
neuronal injury<\/td>1.4142135623731<\/td>\n<\/tr>\n
montplaisir jy<\/td>1.4142135623731<\/td>\n<\/tr>\n
bertrand ja<\/td>1.4142135623731<\/td>\n<\/tr>\n
antiemetic domperidone<\/td>1.4142135623731<\/td>\n<\/tr>\n
frequent monitoring<\/td>1.4142135623731<\/td>\n<\/tr>\n
weaver fm<\/td>1.4142135623731<\/td>\n<\/tr>\n
kayser?fleischer rings<\/td>1.4142135623731<\/td>\n<\/tr>\n
personal fees<\/td>1.4142135623731<\/td>\n<\/tr>\n
recommendations of experts<\/td>1.4142135623731<\/td>\n<\/tr>\n
similar antidepressants<\/td>1.4142135623731<\/td>\n<\/tr>\n
thompson jp<\/td>1.4142135623731<\/td>\n<\/tr>\n
integrated healthcare<\/td>1.4142135623731<\/td>\n<\/tr>\n
intracytoplasmic inclusions<\/td>1.4142135623731<\/td>\n<\/tr>\n
reward processing<\/td>1.4142135623731<\/td>\n<\/tr>\n
mayo foundation<\/td>1.4142135623731<\/td>\n<\/tr>\n
stool softeners<\/td>1.4142135623731<\/td>\n<\/tr>\n
.0 b013e31822c9123<\/td>1<\/td>\n<\/tr>\n
.0 b013e3181d55f24<\/td>1<\/td>\n<\/tr>\n
0.4 hour<\/td>1<\/td>\n<\/tr>\n
.0 b013e318225ab66<\/td>1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":2257,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-2462","page","type-page","status-publish","hentry"],"aioseo_notices":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/P9nUTT-DI","jetpack_likes_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/comments?post=2462"}],"version-history":[{"count":1,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2462\/revisions"}],"predecessor-version":[{"id":2463,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2462\/revisions\/2463"}],"up":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2257"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/media?parent=2462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}